Results 251 to 260 of about 136,428 (330)

Research progress on oral glucagon-like peptide-1 receptor agonists in the treatment of diabetes mellitus type 2. [PDF]

Front Mol Biosci
Shao Q, Xiong J, Wu J, Mao J, Hu Q.
europepmc   +1 more source

Perioperative management of long-acting glucagon-like peptide-1 (GLP-1) receptor agonists. Comment on Br J Anaesth 2024; 132: 644–8 [PDF]

Paul Potnuru, Nadia Hernandez, Omonele O. Nwokolo, Sudipta Sen   +3 more
openalex   +1 more source

Association between glucagon‐like peptide‐1 receptor agonists and risk of dementia in older adults with type 2 diabetes: A target trial emulation

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aim Type 2 diabetes (T2D) is associated with increased dementia risk, but comparative data across newer glucose‐lowering therapies remain limited. We examined whether the initiation of GLP‐1 receptor agonists (GLP‐1 RAs) was associated with incident dementia compared with DPP4 inhibitors (DPP4is) and SGLT2 inhibitors (SGLT2is) in older adults ...
Ting Zhou, Huilin Tang, Bingyu Zhang, Dazheng Zhang, Yiwen Lu, Lu Li, Jiajie Chen, Yong Chen, David A. Asch, Yong Chen   +9 more
wiley   +1 more source

The Role of Glucagon-like Peptide-1 Receptor Agonists in Alzheimer's and Parkinson's Disease: A Literature Review of Clinical Trials. [PDF]

Life (Basel)
Pilśniak J, Węgrzynek-Gallina J, Bednarczyk B, Buczek A, Pilśniak A, Chmiela T, Jarosińska A, Siuda J, Holecki M.   +8 more
europepmc   +1 more source

Immunohistochemical and Morphometrical Studies on the Distribution of Glucagon-like Peptide-1 (GLP-1)-immunoreactive Cells in the Chicken Intestine

, 2005
Kohzy Hiramatsu, Asa Yamasaki, Tomomi Shioji   +2 more
openalex   +2 more sources

Literature‐informed ensemble machine learning for three‐year diabetic kidney disease risk prediction in type 2 diabetes: Development, validation, and deployment of the PSMMC NephraRisk model

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Introduction Diabetic kidney disease (DKD) and diabetic nephropathy (DN) affect around 40% of diabetic patients but lack accurate risk prediction tools that include social determinants and demographic complexity. We developed and validated an ensemble machine learning model for three‐year DKD/DN risk prediction with deployment readiness ...
Ayla M. Tourkmani, Turki J. Al‐Harbi, Ahmad Abdullah Alghamdi, Ibrahim M. Youzghadli, Faris Saad Alosaimi, Ahmed Y. Azzam   +5 more
wiley   +1 more source

Effects of insulin and the glucagon‐like peptide 1 receptor agonist liraglutide on the kidney proteome in db/db mice

, 2017
Leena Liljedahl, Jenny Norlin, James N. McGuire, Peter James   +3 more
openalex   +1 more source

Mental health changes after 4 months of weight loss treatment with the glucagon‐like peptide‐1 analogue liraglutide 3.0 mg

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Objective This observational study examined changes in mental health and wellbeing after 4‐months liraglutide 3.0 mg treatment in patients with obesity and explored associations with weight loss. Methods We included 98 patients with obesity treated with liraglutide 3.0 mg.
Susanne Kuckuck, Nina van Gerwen, Johanneke E. Oosterman, Mesut Savas, Maryam Kavousi, Brenda W. J. H. Penninx, Mariëtte R. Boon, Elisabeth F.C. van Rossum   +7 more
wiley   +1 more source

Successful Use of Glucagon-Like Peptide-1 Receptor Agonist in a Patient With Recurrent Hypertriglyceridemia-Induced Pancreatitis. [PDF]

ACG Case Rep J
Guralwar C, Mitsuhashi S, Ashkar M, Chedid VG.   +3 more
europepmc   +1 more source

Duodenal infusion of fatty acids differentially affects plasma glucagon-like peptide-1 and ghrelin concentrations in sheep

, 2018
Rika Fukumori, Yoji Masuda, Ayaka Takeuchi, Rina Yanai, Khurchabiling Atchalalt, Borjigin Sarentonglaga, Kazuko Ogata, M. Yamaguchi, Asuka Hara, Akane Sato, Toshihisa Sugino, Yoshikazu Nagao   +11 more
openalex   +2 more sources